Neurology Today in 5

By American Academy of Neurology

What's Neurology Today in 5 about?

Joseph E. Safdieh, MD, FAAN, Editor-in-Chief of Neurology Today highlights the most noteworthy and newsworthy neurology stories in the issue.

Download our free app to listen on your phone

Neurology Today in 5 episodes:

06.20.2024
When to withdraw life support for severe TBI, inflammatory markers score and stroke risk, application overload for neurology residency programs.
In this week’s podcast, Neurology Today’s editor-in-chief discusses a paper advising against prematurely withdrawing life support for severe TBI, data showing those with the highest composite score of inflammatory markers had a greater risk for stroke, original reporting stressing...
06.06.2024
Code for ICH, new findings on Havana syndrome, distal symmetric polyneuropathy underdiagnosed in low income primary care clinics
In this week’s podcast, Neurology Today’s editor-in-chief discusses a push among neurocritical care experts to develop a code procedure for intracerebral hemorrhage, new findings showing people with Havana syndrome have functional neurologic disorder, and a study reporting distal symmetric...
05.16.2024
Surgical removal of hematoma in ICH, disparities in neurodiagnosis for epilepsy, inequities among female neurology researchers
In this week’s podcast, Neurology Today’s editor-in-chief discusses a new study reporting better outcomes with surgical removal of hematoma in intracerebral hemorrhage, disparities in access to diagnosis and care for epilepsy, and the challenges that remain for women in...
05.02.2024
Generative AI for personal statements, Match Day and neurology, AHS statement on CGRP-targeting therapies
Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new articles that discuss program directors’ response to the use of generative AI for personal statements, the good news for neurology based on the 2024 Match Day, and the AHS...
04.18.2024
ME/CFS and long COVID; negative outcomes for ALS drug; donanemab
Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that explores an association between myalgic encephalomyelitis/chronic fatigue and long COVID; negative phase 3 findings on AMX0035 for ALS, and the pending approval of donanemab for Alzheimer’s disease.
04.04.2024
BTK inhibitors for MS, lecanemab, neurologic adverse effects and COVID vaccine
Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that casts doubt on the future of BTK inhibitors for MS, an assessment of the cost-effectiveness of lecanemab, and findings that COVID vaccines are not significantly associated with adverse neurologic...
03.21.2024
SARS-CoV-2 and dopamine neurons, valproate risks for men, neurologists on locum tenens
Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new stories reporting on the impact of SARS-CoV2 on dopamine neurons, a European Medicines Agency warning about valproate risks for men, and neurologists on the pros and cons of working...
03.07.2024
AI and 911 stroke detection, iatrogenic Alzheimer’s and human growth hormone, seizure dogs and refractory epilepsy
Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new stories reporting on the use of AI in EMS systems for stroke detection, the association between human growth hormone and iatrogenic Alzheimer’s, and seizure dogs for refractory epilepsy.
$AI and 911 stroke detection, iatrogenic Alzheimer’s and human growth hormone, seizure dogs and refractory epilepsy$
02.12.2024
Biomarker for migraine; posterior cortical atrophy gene therapy for neuromuscular disorders
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses a new study showing retinal vascular perfusion as a migraine biomarker, clinical and pathophysiological correlates of posterior cortical atrophy, and advances in gene therapies for neuromuscular disorders.
01.25.2024
Cerebral amyloid angiopathy and nontraumatic subdural hemorrhage, AI for neurology boards, weight loss drugs and neurologic conditions
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing the cerebral amyloid angiopathy as a risk factor for nontraumatic subdural hemorrhage, AI beats humans in neurology-like boards, and the impact of popular weight loss drugs on neurologic...
01.16.2024
Rising incidence of Creutzfeldt-Jakob disease, therapy for prodromal migraine, neurotrauma of blast injury
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing the rising incidence of Creutzfeldt-Jakob disease, an effective therapy for prodromal migaine, and neuroinflammation in military personnel exposed to blast injury.
01.02.2024
DBS and cognition in severe TBI, in utero exposure to antiseizure drugs, best advances of 2023
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies on the impact of deep brain stimulation on cognition in severe traumatic brain injury and how adaptive functioning is impacted in children exposed to antiseizure drugs in utero, and...
12.21.2023
Parkinson’s and suicide risk; biomarkers and underrepresentation in Alzheimer’s trials, immune system changes in ALS and Parkinson’s.
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing double the suicide risk among Parkinson’s patients; underrepresentation of non-White people in Alzheimer’s trial related to biomarker eligibility; early immune systems changes may play early role...
12.07.2023
Serotonin and long COVID, Afib detected 3 years after stroke, Medicare on PET amyloid scans
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing serotonin depletion associated with long COVID; implantable cardiac monitors detect Afib 3 years post-stroke; and what Medicare’s decision to cover PET amyloid scans means for neurologists.
11.16.2023
A promising drug for refractory epilepsy; adverse childhood events and headache disorders; pathological engulfment by microglia in dementia.
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies on a promising potassium channel opener for refractory epilepsy; the impact of adverse childhood events in headache disorders; and excessive engulfment by microglia/astroctyes in dementia.
$A promising drug for refractory epilepsy; adverse childhood events and headache disorders; pathological engulfment by microglia in dementia.$
11.02.2023
Blood transfusions and spontaneous intracerebral hemorrhages, long distance travel to neurologists, biomarkers for Parkinson’s disease
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new research on the risk of spontaneous intracerebral hemorrhages after blood transfusions; the burden of long distance travel to see neurologists; and two promising biomarkers for early diagnosis of Parkinson’s disease.
10.19.2023
Blood pressure and endovascular therapy, cutbacks in neurology CME, blood test for Alzheimer’s
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new research on blood pressure targets for stroke after endovascular therapy, changing policies on CME, and a direct-to-consumer blood test for Alzheimer’s disease.
10.05.2023
Football and Parkinson’s, deep brain stimulation for stroke recovery, neuroprostheses for anarthric patients
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new research on football and the risk for Parkinson’s disease, the potential of deep brain stimulation for recovery from stroke, and neuroprostheses for patients with anarthria.
09.21.2023
Medicare coverage of carotid stenting, disparities in vulnerable neuro-oncology patients, optical EMG for neuromuscular disorders.
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses the Medicare’s proposed coverage of carotid stenting in asymptomatic patients,neuro-oncologists’ perspectives on a federal initiative to target persistent poverty in vulnerable patients, and the technological promise of a new...
09.07.2023
Endovascular treatment and intracranial tumors; guideline on IVIG use for neuromuscular disorders, pros and cons of donanemab.
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses research that assesses the safety of endovascular treatment post-stroke for people with intracranial tumors, the AANEM guideline on IVIG use for neuromuscular disorders, and the latest data on donanemab.
08.17.2023
Oral health and cognitive decline; managing first-ever sleep seizures; growth of concierge neurology.
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses studies that associate poor oral health and risk for cognitive decline and how to manage first-ever sleep seizures that recur as well as the growth of concierge neurology.
08.03.2023
Gene variants and MS severity, AI and EEG reads, neuroprotective agent for ischemic stroke
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses studies that identify gene variants associated with MS severity/progression, an AI program that read EEGs accurately, and butylphthalide as a promising neuroprotective agent for ischemic stroke.
07.20.2023
Antigen tolerance in mouse MS model, epileptiform activity and ICU outcomes, agent slows gliomas.
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses a novel therapeutic approach that induced antigen tolerance in an MS mouse model, the association between epileptiform activity and ICU outcomes, and an agent, vorasidenib, that slows low-grade gliomas.
07.06.2023
Gout and risk of neurodegenereative diseases, Tenecteplase compared with warfarin, cognitive decline after heart attack
In this week’s podcast, Neurology Today’s editor-in-chief discusses the association between gout and neurodegenerative diseases, tenecrteplase vs.warfarin for acute stroke, expedited cognitive decline after a heart attack.
06.15.2023
Antipsychotic for dementia-related agitation, contaminated water at Camp Lejeune associated with elevated risk for Parkinson’s, gene variant confers resilience against autosomal dominant Alzheimer’s.
In this week’s podcast, Neurology Today’s editor-in-chief discusses the FDA approval of an antipsychotic for agitation in dementia, elevated risk for Parkinson’s in Camp Lejeune Marines exposed to contaminated water, a gene variant delays the onset of symptoms in man...
06.01.2023
OnabotulinumtoxinA for pregnant women with migraine, adderrall shortage, AI for epilepsy
In this week’s podcast, Neurology Today’s editor-in-chief discusses a study on the safety of omnabotuliumtoxinA on pregnant women with migraine, the impact of the Adderall shortage on patients with ADHD and narcolepsy, and the state of AI for epilepsy. This...
05.18.2023
Assay detects Parkinson’s before symptom onset; life stressors in pregnant women with epilepsy; role of inflammation in NORSE
In this week’s podcast, Neurology Today’s editor-in-chief discusses a new study reporting a gene assay detected Parkinson’s before symptoms onset, life stressors greatly impact women with epilepsy during pregnancy; the role of inflammation in new-onset refractory status epilepticus. This podcast...
05.04.2023
Anticoagulants for patients with dementia and Afib, tau levels in women taking hormone replace therapy, neurohumanities programs for neurology residents.
In this week’s podcast, Neurology Today’s editor-in-chief discusses a new study finding anticoagulants are safe for patients with atrial fibrillation and dementia, women on hormone replacement therapy had higher tau levels, and neurology residents are participants in humanities programs...
04.20.2023
Fertility treatments for women with MS, stroke systems of care, ravalizumab for NMOSD
In this week’s podcast, Neurology Today’s editor-in-chief discusses a new study finding fertility treatments did not lead to MS relapses for women, a AHA consensus statement that finds stroke systems need improvement, and ravalizumab at less frequent doses was...
04.06.2023
Intranasal CGRP for migraine, ultrasound ablation for Parkinson’s disease, novel therapeutic pathway for Duchenne muscular atrophy.
In this week’s podcast, Neurology Today’s editor-in-chief discusses the newly approved zavegepant for migraine, the potential/caveats of ultrasound ablation for Parkinson’s disease, the transational potential of a new therapeutic target for Duchenne muscular atrophy.
03.16.2023
Antipsychotics and dementia risk; biomarkers for lecanemab eligibility; trial of difelikefalin for neurogenic itch in notaliga paresthetica.
In this week’s podcast, Neurology Today’s editor-in-chief discusses the increased use of antipsychotics during the pandemic and an associated greater risk for dementia, determining the best biomarkers when considering lecanemab for Alzheimer’s, and a novel approach for managing uncomfortable...
03.02.2023
Pregnancy-associated stroke outcomes; a robotic device for shoulder movement in ALS; non-invasive neurostimulation for refractory seizures.
In this week’s podcast, Neurology Today’s editor-in-chief discusses long-term adverse outcomes from pregnancy-associated stroke, a robotic device to assist shoulder movement in ALS, and the promise of neurostimulation for refractory seizures in the ICU.
$Pregnancy-associated stroke outcomes; a robotic device for shoulder movement in ALS; non-invasive neurostimulation for refractory seizures.$
02.16.2023
Acute infections and increased risk for dementia, alternatives to CPAP for sleep apnea; the legacy of Dr. Ralph Sacco.
In this week’s podcast, Neurology Today’s editor-in-chief discusses the associated risk between acute infections and dementia; alternative therapies to CPAP for sleep apnea; and Dr. Ralph Sacco’s impact on the field.
02.02.2023
IV thrombolysis for large vessel occlusion; impact of mindfulness, exercise on cognition;new brain layer in subarachnoid space.
In this week’s podcast, Neurology Today’s editor-in-chief discusses the report on outcomes of IV thrombolysis for large vessel occlusions; the discovery of a new brain layer in the subarachnoid space; and the impact of mindfulness and exercise on cognition.
01.19.2023
Best advances of 2022, misdiagnosed autoimmune encephalitis, inflation his neurology private practice
In this week’s podcast, Neurology Today’s editor-in-chief discusses the report on misdiagnosis of autoimmune encephalitis, inflationary times for neurologists in private practice, and the editorial board picks for best advances in 2022.
01.04.2023
Spinal cord stimulation for chronic pain, disparities in brain age by race/ethnicity, careers in teleneurology
In this week’s podcast, Neurology Today’s editor-in-chief discusses a comparison of spinal cord stimulation with medical management for chronic pain, earlier brain aging in Black people, and the pros/cons of working for teleneurology companies.
12.15.2022
Rituximab for MS, food security and cognition, in utero treatment for Pompe disease
In this week’s podcast, Neurology Today’s editor-in-chief discusses why MS specialists advocate for rituximab for MS, how food security may relate to cognition, and a novel in utero therapy for Pompe diseasea.
12.01.2022
Modifiable risk factors for monogenic stroke, health care systems prepare for wave of new Alzheimer’s therapies, criteria for selecting neurology residents
In this week’s podcast, Neurology Today’s editor-in-chief discusses modifiable risk factors for monogenic stroke, what health care systems need to do to prepare for new Alzheimer’s therapies, and criteria program directors apply in selecting neurology residents.
11.17.2022
Revascular therapies for stroke patients with COVID, dementia and suicide risk, hyperbaric oxygen therapy for concussion in children.
In this week’s podcast, Neurology Today’s editor-in-chief discusses data suggesting revascular therapies are safe for patients with stroke and COVID, dementia is associated with increased suicide risk, and the potential of hyperbaric oxygen therapy for children with concussion.
11.03.2022
Allergies and dementia risk, folic acid and risk of cancer in children of women with epilepsy, climate change and neurologic disorders.
In this week’s podcast, Neurology Today’s editor-in-chief discusses data suggesting allergic disease is associated with an increased risk of dementia, an increased risk of cancer in children born to women with epilepsy who took high-dose folic acid in pregnancy, and...
10.20.2022
Vamorolone for DMD, aquaporin protein and amyloid clearance, monkey pox-associated neurologic events.
In this week’s podcast, Neurology Today’s editor-in-chief discusses data suggesting vamorolone as an alternative to corticosteroids for Duchenne muscular dystrophy, how an aquaporin protein promotes amyloid clearance, and neurologic events associated with monkeypox virus.
10.06.2022
Chronic kidney disease and risk for intracerebral hemorrhage, gonadotropic replacement and cogntion in Down syndrome, how to distinguish polio from other viruses
In this week’s podcast, Neurology Today’s editor-in-chief discusses new findings on chronic kidney disease and risk for intracerebral hemorrhage, the potential of gonadotropic replacement for improving cognition in Down syndrome, and distinguishing polio from acute flaccid myelitis and other viruses.
09.15.2022
Decompression and Chiari malformation, atrial cardiopathy and dementia risk, 3D printing the brain.
In this week’s podcast, Neurology Today’s editor-in-chief discusses new findings on decompression for Chiari malformation, the association of atrial cardiopathy with dementia, and a neurology resident’s 3D printing of brain model.
09.01.2022
Processed foods and dementia risk, therapies for vertigo, impostor syndrome
In this week’s podcast, Neurology Today’s editor-in-chief discusses the increased associated risk between processed foods and dementia risk, antihistamines vs. benzodiazepines for vertigo, and impostor syndrome in neurology.
08.18.2022
Spinal cord stimulation for diabetic neuropathy, Roe v. Wade reversal, diversifying the neurology pipeline.
In this week’s podcast, Neurology Today’s editor-in-chief discusses spinal cord stimulation for painful diabetic neuropathy, the Roe v. Wade reversal and neurology, and initiatives to diversify the neurology pipeline.
08.04.2022
Functional neurologic disorder, newborn screening for SMA, when to leave job
In this week’s podcast, Neurology Today’s editor-in-chief discusses new thinking about functional neurologic disorders, the benefits of screening newborns for spinal muscular atrophy, and career advice on when to leave a job in neurology.
07.21.2022
Brain aneurysm rupture, COVID-19 exposure in utero, socioeconomics and brain development.
In this week’s podcast, Neurology Today’s editor-in-chief discusses RAAS inhibitors for brain aneurysm rupture, the impact of COVID-19 on babies exposed in utero, and how socioeconomic status, independent of genetics, affects brain development.
07.07.2022
Monkeypox, soticelstat for epilepsy, gabapentin for stroke recovery.
In this week’s podcast, Neurology Today’s editor-in-chief discusses what’s known about monkeypox, soticelstat as a potential new epilepsy therapy, and the potential of gabapentin for stroke recovery.
06.16.2022
Fenfluramine for LGS, social isolation and dementia risk, neurology’s status in NRMP match.
In this week’s podcast, Neurology Today’s editor-in-chief discusses the approval of fenfluramine for Lennox-Gastaut syndrome, how social isolation affects dementia risk, and the competitiveness of neurology in this year’s residency match.
06.02.2022
Teleneurology in rural America, trauma-informed neurology,advances in neurogenetics
In this week’s podcast, Neurology Today’s editor-in-chief discusses the challenges and opportunities of teleneurology in rural areas, the effect of childhood trauma on neurologic disorders, and genetics advances in neurology.

What's Neurology Today in 5 about?

Download our free app to listen on your phone

Neurology Today in 5 episodes:

When to withdraw life support for severe TBI, inflammatory markers score and stroke risk, application overload for neurology residency programs.

Code for ICH, new findings on Havana syndrome, distal symmetric polyneuropathy underdiagnosed in low income primary care clinics

Surgical removal of hematoma in ICH, disparities in neurodiagnosis for epilepsy, inequities among female neurology researchers

Generative AI for personal statements, Match Day and neurology, AHS statement on CGRP-targeting therapies

ME/CFS and long COVID; negative outcomes for ALS drug; donanemab

BTK inhibitors for MS, lecanemab, neurologic adverse effects and COVID vaccine

SARS-CoV-2 and dopamine neurons, valproate risks for men, neurologists on locum tenens

AI and 911 stroke detection, iatrogenic Alzheimer’s and human growth hormone, seizure dogs and refractory epilepsy

Biomarker for migraine; posterior cortical atrophy gene therapy for neuromuscular disorders

Cerebral amyloid angiopathy and nontraumatic subdural hemorrhage, AI for neurology boards, weight loss drugs and neurologic conditions

Rising incidence of Creutzfeldt-Jakob disease, therapy for prodromal migraine, neurotrauma of blast injury

DBS and cognition in severe TBI, in utero exposure to antiseizure drugs, best advances of 2023

Parkinson’s and suicide risk; biomarkers and underrepresentation in Alzheimer’s trials, immune system changes in ALS and Parkinson’s.

Serotonin and long COVID, Afib detected 3 years after stroke, Medicare on PET amyloid scans

A promising drug for refractory epilepsy; adverse childhood events and headache disorders; pathological engulfment by microglia in dementia.

Blood transfusions and spontaneous intracerebral hemorrhages, long distance travel to neurologists, biomarkers for Parkinson’s disease

Blood pressure and endovascular therapy, cutbacks in neurology CME, blood test for Alzheimer’s

Football and Parkinson’s, deep brain stimulation for stroke recovery, neuroprostheses for anarthric patients

Medicare coverage of carotid stenting, disparities in vulnerable neuro-oncology patients, optical EMG for neuromuscular disorders.

Endovascular treatment and intracranial tumors; guideline on IVIG use for neuromuscular disorders, pros and cons of donanemab.

Oral health and cognitive decline; managing first-ever sleep seizures; growth of concierge neurology.

Gene variants and MS severity, AI and EEG reads, neuroprotective agent for ischemic stroke

Antigen tolerance in mouse MS model, epileptiform activity and ICU outcomes, agent slows gliomas.

Gout and risk of neurodegenereative diseases, Tenecteplase compared with warfarin, cognitive decline after heart attack

Antipsychotic for dementia-related agitation, contaminated water at Camp Lejeune associated with elevated risk for Parkinson’s, gene variant confers resilience against autosomal dominant Alzheimer’s.

OnabotulinumtoxinA for pregnant women with migraine, adderrall shortage, AI for epilepsy

Assay detects Parkinson’s before symptom onset; life stressors in pregnant women with epilepsy; role of inflammation in NORSE

Anticoagulants for patients with dementia and Afib, tau levels in women taking hormone replace therapy, neurohumanities programs for neurology residents.

Fertility treatments for women with MS, stroke systems of care, ravalizumab for NMOSD

Intranasal CGRP for migraine, ultrasound ablation for Parkinson’s disease, novel therapeutic pathway for Duchenne muscular atrophy.

Antipsychotics and dementia risk; biomarkers for lecanemab eligibility; trial of difelikefalin for neurogenic itch in notaliga paresthetica.

Pregnancy-associated stroke outcomes; a robotic device for shoulder movement in ALS; non-invasive neurostimulation for refractory seizures.

Acute infections and increased risk for dementia, alternatives to CPAP for sleep apnea; the legacy of Dr. Ralph Sacco.

IV thrombolysis for large vessel occlusion; impact of mindfulness, exercise on cognition;new brain layer in subarachnoid space.

Best advances of 2022, misdiagnosed autoimmune encephalitis, inflation his neurology private practice

Spinal cord stimulation for chronic pain, disparities in brain age by race/ethnicity, careers in teleneurology

Rituximab for MS, food security and cognition, in utero treatment for Pompe disease

Modifiable risk factors for monogenic stroke, health care systems prepare for wave of new Alzheimer’s therapies, criteria for selecting neurology residents

Revascular therapies for stroke patients with COVID, dementia and suicide risk, hyperbaric oxygen therapy for concussion in children.

Allergies and dementia risk, folic acid and risk of cancer in children of women with epilepsy, climate change and neurologic disorders.

Vamorolone for DMD, aquaporin protein and amyloid clearance, monkey pox-associated neurologic events.

Chronic kidney disease and risk for intracerebral hemorrhage, gonadotropic replacement and cogntion in Down syndrome, how to distinguish polio from other viruses

Decompression and Chiari malformation, atrial cardiopathy and dementia risk, 3D printing the brain.

Processed foods and dementia risk, therapies for vertigo, impostor syndrome

Spinal cord stimulation for diabetic neuropathy, Roe v. Wade reversal, diversifying the neurology pipeline.

Functional neurologic disorder, newborn screening for SMA, when to leave job

Brain aneurysm rupture, COVID-19 exposure in utero, socioeconomics and brain development.

Monkeypox, soticelstat for epilepsy, gabapentin for stroke recovery.

Fenfluramine for LGS, social isolation and dementia risk, neurology’s status in NRMP match.

Teleneurology in rural America, trauma-informed neurology,advances in neurogenetics

Other shows like Neurology Today in 5: